Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 142 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study sites revised (138)v142
  2. Re-verified, no change to tracked fieldsv141
  3. Study sites revised (138)v140
  4. Study completion date: Oct 22, 2025 to Oct 23, 2026v139
  5. Site details revised at 1 of 138 sitesv138
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (138)v137
  2. Study sites revised (138)v136
  3. Re-verified, no change to tracked fieldsv135
  4. Study sites revised (138)v134
  5. Study sites revised (138)v133
  6. Study completion date: Oct 22, 2024 to Oct 22, 2025
    • Study sites revised (138)
    v132
  7. Re-verified, no change to tracked fieldsv131
  8. Study sites revised (138)v130
  9. 2 versions Re-verified since Jun 6, 2024, no change to tracked fieldsv128-v129
  10. Study sites revised (138)v127
  11. Study sites revised (138)v126
  12. Study sites revised (138)v125
  13. Re-verified, no change to tracked fieldsv124
  14. Study completion date: Oct 22, 2024
    • Start date: Oct 26, 2004 to Nov 3, 2004
    v123
  15. Re-verified, no change to tracked fieldsv122
  16. Study sites revised (138)v121
  17. Re-verified, no change to tracked fieldsv120
  18. Study sites revised (138)v119
  19. Re-verified, no change to tracked fieldsv118
  20. Study sites revised (138)v117
  21. Site details revised at 1 of 138 sitesv116
  22. 3 versions Re-verified since May 7, 2022, no change to tracked fieldsv113-v115
  23. Study sites revised (138)v112
  24. Re-verified, no change to tracked fieldsv111
  25. Study sites revised (138)v110
  26. Study sites revised (138)v109
  27. 2 versions Re-verified since Apr 28, 2021, no change to tracked fieldsv107-v108
  28. Study sites revised (138)v106
  29. Re-verified, no change to tracked fieldsv105
  30. Study sites revised (138)v104
  31. Re-verified, no change to tracked fieldsv103
  32. Study sites revised (138)v102
  33. Study sites revised (138)v101
  34. Study sites revised (138)v100
  35. 2 versions Re-verified since Apr 23, 2020, no change to tracked fieldsv98-v99
  36. Study sites revised (138)v97
  37. Site details revised at 1 of 138 sitesv96
  38. 3 versions Re-verified since Dec 9, 2019, no change to tracked fieldsv93-v95
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
Trial Details
NCT Number NCT00098475
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Enrollment 452 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov